Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPKAPK5 | Q8IW41 | 2/20 | 0.42 |
| ▸ | ATR | Q13535 | 5/20 | 0.39 |
| ▸ | JAK2 | O60674 | 2/20 | 0.38 |
| ▸ | BRD4 | O60885 | 2/20 | 0.38 |
| ▸ | CSF1R | P07333 | 1/20 | 0.38 |
| ▸ | CDK4 | P11802 | 1/20 | 0.38 |
| ▸ | CDK6 | Q00534 | 1/20 | 0.38 |
| ▸ | PIK3CA | P42336 | 5/20 | 0.38 |
| ▸ | MTOR | P42345 | 5/20 | 0.38 |
| ▸ | JAK1 | P23458 | 1/20 | 0.37 |
| ▸ | BRD2 | P25440 | 1/20 | 0.37 |
| ▸ | JAK3 | P52333 | 1/20 | 0.37 |
| ▸ | BRD3 | Q15059 | 1/20 | 0.37 |
| ▸ | BRDT | Q58F21 | 1/20 | 0.37 |
| ▸ | GSK3B | P49841 | 1/20 | 0.37 |
| ▸ | PARP1 | P09874 | 1/20 | 0.37 |
| ▸ | TP53BP1 | Q12888 | 1/20 | 0.35 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.35 |
| ▸ | SMO | Q99835 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13922511 | 0.93 | MAPKAPK5 (0.42) | MAPKAPK5ATRPIK3CAMTORGSK3B | |
| SCHEMBL1685142 | 0.90 | MAPKAPK5 (0.46) | MAPKAPK5ATRJAK2JAK1GSK3B | |
| SCHEMBL1685245 | 0.88 | ATR (0.39) | MAPKAPK5ATRJAK2BRD4CSF1R | |
| SCHEMBL10166023 | 0.86 | CSF1R (0.39) | MAPKAPK5ATRJAK2BRD4CSF1R | |
| SCHEMBL10134341 | 0.85 | MAPKAPK5 (0.44) | MAPKAPK5CSF1RCDK4CDK6PIK3CA | |
| SCHEMBL12618951 | 0.84 | MAPKAPK5 (0.47) | MAPKAPK5JAK2PIK3CAMTORGSK3B | |
| SCHEMBL1685118 | 0.84 | MAPKAPK5 (0.44) | MAPKAPK5ATRGSK3BPARP1TP53BP1 | |
| SCHEMBL14162585 | 0.83 | MAPKAPK5 (0.44) | MAPKAPK5CDK4CDK6PIK3CAMTOR | |
| SCHEMBL10134096 | 0.83 | MAPKAPK5 (0.48) | MAPKAPK5JAK2PIK3CAMTORGSK3B | |
| SCHEMBL14162768 | 0.83 | MAPKAPK5 (0.46) | MAPKAPK5CDK4GSK3B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120010206-A1 | IMIDAZOLOPYRIDINE COMPOUNDS USEFUL FOR THE TREATMENT OF DEGENERATIVE AND INFLAMMATORY DISEASES | GALAPAGOS N. V. (BE) | 2012-01-12 | — | — | US | disclosed |
| US-20120010206-A1 | IMIDAZOLOPYRIDINE COMPOUNDS USEFUL FOR THE TREATMENT OF DEGENERATIVE AND INFLAMMATORY DISEASES | GALAPAGOS N. V. (BE) | 2012-01-12 | — | — | US | disclosed |
| US-20120010206-A1 | IMIDAZOLOPYRIDINE COMPOUNDS USEFUL FOR THE TREATMENT OF DEGENERATIVE AND INFLAMMATORY DISEASES | GALAPAGOS N. V. (BE) | 2012-01-12 | — | — | US | disclosed |
| US-7951818-B2 | Imidazolopyridine compounds useful for the treatment of degenerative and inflammatory diseases | GALAPAGOS NV (BE) | 2011-05-31 | — | — | US | disclosed |
| US-7951818-B2 | Imidazolopyridine compounds useful for the treatment of degenerative and inflammatory diseases | GALAPAGOS NV (BE) | 2011-05-31 | — | — | US | disclosed |
| US-7951818-B2 | Imidazolopyridine compounds useful for the treatment of degenerative and inflammatory diseases | GALAPAGOS NV (BE) | 2011-05-31 | — | — | US | disclosed |
| US-20090048245-A1 | Imidazolopyridine compounds useful for the treatment of degenerative and inflammatory diseases | GALAPAGOS NV (BE) | 2009-02-19 | — | — | US | disclosed |
| US-20090048245-A1 | Imidazolopyridine compounds useful for the treatment of degenerative and inflammatory diseases | GALAPAGOS NV (BE) | 2009-02-19 | — | — | US | disclosed |
| US-20090048245-A1 | Imidazolopyridine compounds useful for the treatment of degenerative and inflammatory diseases | GALAPAGOS NV (BE) | 2009-02-19 | — | — | US | disclosed |
| WO-2008065199-A1 | IMIDAZOLOPYRIDINE COMPOUNDS USEFUL FOR THE TREATMENT OF DEGENERATIVE AND INFLAMMATORY DISEASES | GALAPAGOS N.V. (BE) | 2008-06-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120010206-A1 | IMIDAZOLOPYRIDINE COMPOUNDS USEFUL FOR THE TREATMENT OF DEGENERATIVE AND INFLAMMATORY DISEASES | COL2A1, MMP1, COL1A1 | MAPKAPK5 19/4885ATR 2844/4885JAK2 1510/4885 |
| US-20090048245-A1 | Imidazolopyridine compounds useful for the treatment of degenerative and inflammatory diseases | COL2A1, MMP1, COL1A1 | MAPKAPK5 19/4885ATR 2844/4885JAK2 1510/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.